Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

This study tests a strategy called "bipolar androgen therapy" — alternating between very high and very low testosterone levels — to see if it can re-sensitize advanced prostate cancer to standard hormone-blocking treatments that have stopped working. **You may be eligible if...** - You are 18 years or older with confirmed prostate cancer - Your cancer has spread (metastatic) and is no longer responding to standard hormone-blocking therapy - Your testosterone is at castrate levels (below 50 ng/dL) through surgery or injections - You have already been treated with at least one androgen receptor signaling inhibitor (such as enzalutamide or abiraterone) and your cancer has progressed - Your blood counts and organ function meet the required levels - Your general health is good enough to tolerate treatment (ECOG 0–2) **You may NOT be eligible if...** - Your cancer has not yet been treated with standard hormone-blocking therapies - You have serious cardiovascular, liver, or kidney problems that make treatment unsafe - Your cancer no longer has measurable or evaluable disease Talk to your doctor to see if this trial is right for you.